GLP-2 TZ
A dual GIP and GLP-1 receptor agonist research peptide
- Fulfillment Origin
- us
GLP-2 TZ is the Aurelia product designation for tirzepatide (LY3298176), a long-acting synthetic peptide engineered for dual activity at the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is supplied solely as a laboratory research material.
39-amino-acid dual GIP/GLP-1 receptor agonist peptide with a C20 fatty diacid moiety (tirzepatide / LY3298176)
- Formula
- C225H348N48O68
- Molecular weight
- Approximately 4813 g/mol
- Form
- Lyophilized powder
- CAS / ID
- Tirzepatide / LY3298176 (CAS 2023788-19-2)
Independently tested. Verifiably pure.
Every batch of GLP-2 TZ is reviewed against its independent laboratory documentation before fulfillment.
- HPLC Purity AnalysisReported purity: ≥99% — verify against selected lot COA
- Mass SpectrometryMass spectrometry — verify against selected lot COA
- Heavy Metals ScreeningSee selected lot COA
- Endotoxins (LPS)See selected lot COA
- Sterility TestingSee selected lot COA
- Net Peptide ContentSee selected lot COA
- HPLC Purity
- ≥99% — verify against selected lot COA
- Identity
- Mass spectrometry — verify against selected lot COA
- Endotoxin (LAL)
- See selected lot COA
- Lab
- Independent third-party laboratory — replace with actual COA lab
Not for human or veterinary use. For in-vitro laboratory research only. This product is not intended to diagnose, treat, cure, or prevent any disease.
One molecule. Two incretin receptor pathways.
GLP-2 TZ is the Aurelia product designation for tirzepatide (LY3298176), a 39-amino-acid synthetic peptide with dual activity at the GIP and GLP-1 receptors. This dossier summarizes published research and is not medical guidance.
GIP-based dual agonist
The peptide was engineered from a GIP-related sequence and incorporates activity at both GIPR and GLP-1R.
Imbalanced and biased agonism
Published receptor studies describe stronger relative GIPR engagement and distinct GLP-1R signaling behavior.
C20 fatty diacid conjugation
Acylation supports albumin association and an approximately five-day pharmacokinetic half-life.
Published research observations.
Selected group-level results from randomized clinical studies are presented for research context. They do not predict individual outcomes and do not describe the quality or performance of this commercial research material.
Phase 3 study period
The randomized trial enrolled adults with obesity or overweight without diabetes.
Mean weight change reported
Reported for the 15 mg group at week 72 using the cited efficacy estimand.
Participants enrolled
Consult the paper and registry for inclusion criteria, estimands, discontinuations and safety results.
Illustrative display of SURMOUNT-1 mean percentage body-weight changes at week 72 under the reported efficacy estimand. Review the primary publication for confidence intervals, treatment-regimen estimand results and adverse events.
Two pathways. One molecule.
Tirzepatide integrates GIPR and GLP-1R agonism into one peptide. The combined pharmacology is more specific than simply adding the effects of two separate ligands.
Glucose-dependent insulinotropic polypeptide receptor
A Gs-coupled incretin receptor involved in glucose-dependent signaling and metabolic regulation.
Glucagon-like peptide-1 receptor
An incretin receptor associated with glucose-dependent insulin signaling, glucagon regulation and appetite-related research.
Dual-receptor signaling
Published work describes GIPR-weighted engagement and biased GLP-1R signaling relative to native GLP-1.
Where GLP-2 TZ fits.
This comparison organizes research molecules by receptor targets. It is not a comparison of approved indications, clinical suitability, safety or commercial products.
GLP-1 receptor
A single primary incretin receptor target.
GIP + GLP-1
Tirzepatide combines two incretin receptor pathways.
GIP + GLP-1 + glucagon
Investigational triple-receptor molecules add GCGR activity.
| Research molecule | GIPR | GLP-1R | GCGR | Receptor profile |
|---|---|---|---|---|
| Semaglutide | — | Agonist | — | Single GLP-1 receptor agonist |
| Tirzepatide / GLP-2 TZ | Agonist | Agonist | — | Dual GIP/GLP-1 receptor agonist |
| Retatrutide / GLP-3 RT | Agonist | Agonist | Agonist | Investigational triple agonist |
Dual agonism visualized.
Published cellular work describes an imbalanced dual-agonist profile. The qualitative bars explain relative receptor engagement and are not interchangeable with assay-specific EC50 or Emax values.
~5-day half-life. C20 fatty diacid.
Clinical pharmacokinetic studies report an approximately five-to-six-day half-life. A C20 fatty diacid moiety contributes to prolonged exposure and supports once-weekly clinical investigation.
Pharmacokinetic half-life
Approximately five to six days across published clinical pharmacology studies.
Fatty diacid moiety
The acylated side chain contributes to extended systemic exposure.
Synthetic linear peptide
A 39-amino-acid peptide with a linker and lipid moiety.
This is a simplified half-life illustration, not measured concentration-time data and not an administration or dosing guide.
Full specification.
The identity fields describe tirzepatide free-base records. The material actually supplied may differ in salt state, counterions, water content or assay basis, so the selected lot COA remains controlling.
LY3298176
Development identifier associated with tirzepatide.
C225H348N48O68
Reported for tirzepatide in the PubChem compound record.
~4813 g/mol
Nominal mass; verify the exact supplied form against the lot documentation.
39 residues
Synthetic linear peptide with non-native residues and lipid conjugation.
2023788-19-2
Verify the identifier and chemical form against your supplier record.
See selected COA
Purity, identity, content, water and other measurements are lot-specific.
A broad clinical research program. Most recent first.
Tirzepatide development status and approved labeling can change. This research timeline is intentionally concise; verify current status in primary publications, trial registries and applicable regulatory sources.
SURMOUNT-5 head-to-head results published
A phase 3b trial compared maximum tolerated tirzepatide and semaglutide doses over 72 weeks in adults with obesity without diabetes.
SURMOUNT-1 phase 3 results published
The randomized placebo-controlled trial reported weight-related outcomes across 5, 10 and 15 mg groups over 72 weeks.
SURPASS-2 results published
The phase 3 study compared tirzepatide with semaglutide 1 mg in adults with type 2 diabetes over 40 weeks.
Dual-receptor signaling characterized
Cellular pharmacology research described imbalanced GIPR/GLP-1R engagement and biased GLP-1R signaling.
Stability specs.
Storage and prepared-solution stability are formulation-, container- and lot-specific. The actual supplier specification must replace the conservative placeholders below.
Follow the product label
Protect the lyophilized material from conditions outside its documented storage range.
Minimize exposure
Keep the vial closed and use appropriate laboratory handling and monitoring.
Use validated stability data
Stability depends on diluent, pH, concentration, container, temperature and handling.
- Verify the lotMatch the vial identifier to its COA and supplier specification.
- Confirm storageUse only the documented temperature, light and moisture conditions.
- Use a validated protocolPrepare laboratory material using qualified equipment and a documented method.
- Record the preparationDocument lot, diluent, concentration, container, date, operator and disposition.
All featured research on Tirzepatide.
Use the filters to review selected clinical, mechanistic and registry sources. Open the primary record for methods, limitations, conflicts of interest and current status.
Randomized, double-blind, placebo-controlled phase 3 trial in 2,539 adults with obesity or overweight without diabetes, evaluating 5, 10 and 15 mg groups through 72 weeks.
View primary source →Phase 3 active-comparator trial reporting glycated hemoglobin, body-weight and safety outcomes over 40 weeks.
View primary source →Phase 3b head-to-head trial comparing maximum tolerated tirzepatide and semaglutide doses over 72 weeks.
View primary source →Receptor pharmacology study examining relative receptor engagement, cAMP signaling, beta-arrestin recruitment and receptor internalization.
View primary source →Clinical pharmacology study reporting an approximately five-to-six-day plasma half-life and supporting extended exposure.
View primary source →Registry record for NCT04184622, including protocol identifiers, enrollment, study dates and posted results.
View primary source →References.
Primary publications, government compound data and the trial registry used for this dossier.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.Open source ↗
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021.Open source ↗
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025.Open source ↗
- Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020.Open source ↗
- National Center for Biotechnology Information. PubChem Compound Summary for Tirzepatide, CID 156588324.Open source ↗
- ClinicalTrials.gov. NCT04184622 — SURMOUNT-1.Open source ↗
Related products
5-Amino-1MQ
GLP-3 RT
